Very exciting platform, extending BindCraft-style design to antibodies. Spinning it up for testing now...
The ability to design antibodies against any protein of interest has major implications for medicine, biotech, and basic science.
Today, we introduce Germinal, a pipeline for epitope-targeted de novo antibody design achieving 4–22% success rates with efficient experimental validation.